Published online before print November 7, 2002, doi: 10.1161/01.ATV.0000046033.32478.6D
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Brief Reviews |
Hormone Replacement Therapy and Risk of Cardiovascular Disease
Implications of the Results of the Women’s Health Initiative
From the Department of Epidemiology, University of Pittsburgh, Pa.
Correspondence to Lewis H. Kuller, MD, DrPH, University of Pittsburgh, GSPH, Department of Epidemiology, 130 DeSoto St, Pittsburgh, PA 15261. E-mail kullerl{at}edc.pitt.edu
The higher rates of coronary heart disease (CHD), stroke, and venous thrombosis among women taking estrogen and progesterone (E+P) compared with placebo in the Women’s Health Initiative clinical trial have important implications for women’s health. Previous studies in both men and women have shown that estrogen therapy lowers low-density lipoprotein cholesterol and raises high-density lipoprotein cholesterol. The changes in these lipoproteins should be associated with at least a 30% decline in CHD risk. Estrogens increased very-low-density lipoprotein (VLDL) triglyceride levels and C-reactive protein. There is evidence that estrogens increase thrombin generation and fibrinolysis. The increase in VLDL triglycerides may enhance thrombotic risk as well as higher levels of atherogenic lipoproteins, such as dense low-density lipoprotein. Genetic variations in estrogen receptors and thrombosis or fibrinolysis may also be important in risks associated with E+P therapy. The increased risk of CHD and stroke with E+P therapy may be attributable to rise in VLDL triglycerides and thrombosis.
Key Words: coronary heart disease • hormones • estrogen • stroke • clinical trials
This article has been cited by other articles:
 |
|
 |
|
  R. D. Abbott, L. J. Launer, B. L. Rodriguez, G. W. Ross, P.W.F. Wilson, K. H. Masaki, D. Strozyk, J. D. Curb, K. Yano, J. S. Popper, et al. Serum estradiol and risk of stroke in elderly men Neurology, February 20, 2007; 68(8): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Peng, J. T. Clark, J. Prasain, H. Kim, C. R. White, and J. M. Wyss Antihypertensive and cognitive effects of grape polyphenols in estrogen-depleted, female, spontaneously hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R771 - R775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Maric Sex Differences in Cardiovascular Disease and Hypertension: Involvement of the Renin-Angiotensin System Hypertension, September 1, 2005; 46(3): 475 - 476. [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, S. H. Han, M.-S. Shin, J. Y. Ahn, Y. Lee, and E. K. Shin Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study Eur. Heart J., July 2, 2005; 26(14): 1362 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lemieux, Y. Gelinas, J. Lalonde, F. Labrie, K. Cianflone, and Y. Deshaies Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors J. Lipid Res., June 1, 2005; 46(6): 1285 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hermenegildo, P.J. Oviedo, M.C. Garcia-Martinez, M.A. Garcia-Perez, J.J. Tarin, and A. Cano Progestogens stimulate prostacyclin production by human endothelial cells Hum. Reprod., June 1, 2005; 20(6): 1554 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Szymanski, C. M. Kessler, and B. Fernhall Relationship of physical fitness, hormone replacement therapy, and hemostatic risk factors in postmenopausal women J Appl Physiol, April 1, 2005; 98(4): 1341 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Mackey, L. H. Kuller, K. Sutton-Tyrrell, R. W. Evans, R. Holubkov, and K. A. Matthews Hormone Therapy, Lipoprotein Subclasses, and Coronary Calcification: The Healthy Women Study Arch Intern Med, March 14, 2005; 165(5): 510 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, M.-S. Shin, I. Sakuma, J. Y. Ahn, D. K. Jin, H. S. Kim, D. S. Kim, S. H. Han, W.-J. Chung, and E. K. Shin Effects of Conventional or Lower Doses of Hormone Replacement Therapy in Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1516 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. French and R. S. Wright Renal insufficiency and worsened prognosis with STEMI: A call for action J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1544 - 1546. [Full Text] [PDF]
|
|
|
|
 |
|
 O. O. Aalami, T. D. Fang, H. M. Song, and R. P. Nacamuli Physiological Features of Aging Persons Arch Surg, October 1, 2003; 138(10): 1068 - 1076. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh, J. Y. Ahn, D. K. Jin, B.-K. Yoon, H. S. Kim, D. S. Kim, W. C. Kang, S. H. Han, I. S. Choi, and E. K. Shin Significant Differential Effects of Hormone Therapy or Tibolone on Markers of Cardiovascular Disease in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1889 - 1894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Weinbauer, C.-J. Partsch, M. Zitzmann, S. Schlatt, and E. Nieschlag Pharmacokinetics and Degree of Aromatization Rather Than Total Dose of Different Preparations Determine the Effects of Testosterone: A Nonhuman Primate Study in Macaca fascicularis J Androl, September 1, 2003; 24(5): 765 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Baxter, W. F. Young Jr., and P. Webb Cardiovascular Endocrinology: Introduction Endocr. Rev., June 1, 2003; 24(3): 253 - 260. [Full Text] [PDF]
|
|